Immune Checkpoint Inhibitors Market, 2014-2024

News provided by

Nov 26, 2014, 07:47 ET

DUBLIN, Nov. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need.

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). There has been a surge of interest in other classes of immunotherapeutics to manage and treat cancer, including Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Key Topics Covered:

1. Preface

2. Executive Summary

3. Cancer Therapeutics and Immuno-Oncology

4. Current Market Landscape

5. CTLA-4 Inhibitors: Key Molecules and Future Outlook

6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook

7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook

8. Competition in Key Indication Areas

9. Deals and Partnerships

10. Company Profiles

11. Conclusion

12. Appendix 1: Tabulated Data

13. Appendix 2: List of Companies and Organizations

Companies Mentioned: